Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

268.03
-3.3350-1.23%
Volume:635.15K
Turnover:171.23M
Market Cap:473.70B
PE:75.72
High:271.61
Open:270.98
Low:267.81
Close:271.36
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.75
T/O Rate:0.04%
Dividend:6.83
Dividend Rate:2.55%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-79.82
PE(LYR):113.57

Loading ...

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Sep 03

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Sep 03

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Sep 03

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Sep 03

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Allergan Aesthetics Unveils Layered Beauty Report on Global Shift Toward Personalized Aesthetic Care

Reuters
·
Sep 02

AbbVie Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

NetraMark Appoints Abivax Regulatory Chief Keith Fournier to Board

Reuters
·
Sep 01

States Namenda Tablets not Withdrawn for Safety or Effectiveness Reasons - Federal Register

THOMSON REUTERS
·
Aug 31

FDA: Will not Begin Procedures to Withdraw Approval of Abbreviated New Drug Applications That Refer to Namenda Products - Federal Register

THOMSON REUTERS
·
Aug 31

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 31

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

TIPRANKS
·
Aug 29

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Reuters
·
Aug 27

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Reuters
·
Aug 27

Abbvie Submits Regulatory Application to Ema for Skyrizi® (Risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
Aug 27